Skip to content
Subscriber Only

Lilly Surges as Experimental Alzheimer’s Drug Shows Promise

  • Study showed slowing of decline in cognition, daily function
  • Mid-stage results must be confirmed in larger studies
Updated on

Eli Lilly & Co. surged in early trading as its experimental Alzheimer’s drug showed promise in a mid-stage clinical trial, boosting hopes for progress against the debilitating, progressive brain disorder.

The drug, donanemab, slowed decline of a composite measure of patient cognition and function by 32% relative to placebo in patients with early Alzheimer’s, the Indianapolis-based company said Monday in a statement.